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Nutrigenetics/nutrigenomics (the study of the bidirectional interactions between genes 
and diet) is a rapidly developing field that is changing research and practice in human 
nutrition. Though eventually nutrition clinicians may be able to provide personalized 
nutrition recommendations, in the immediate future they are most likely to use this 
knowledge to improve dietary recommendations for populations. Currently, estimated 
average requirements are used to set dietary reference intakes because scientists can-
not adequately identify subsets of the population that differ in requirement for a nutri-
ent. Recommended intake levels must exceed the actual required intake for most of 
the population in order to assure that individuals with the highest requirement ingest 
adequate amounts of the nutrient. As a result, dietary reference intake levels often are 
set so high that diet guidelines suggest almost unattainable intakes of some foods. Once 
it is possible to identify common subgroups that differ in nutrient requirements using 
nutrigenetic/nutrigenomic profiling, targeted interventions and recommendations can 
be refined. In addition, when a large variance exists in response to a nutrient, statistical 
analyses often argue for a null effect. If responders could be differentiated from nonre-
sponders based on nutrigenetic/nutrigenomic profiling, this statistical noise could be 
eliminated and the sensitivity of nutrition research greatly increased.
Challenges for Clinical Nutrigenetics/Nutrigenomics
The first challenge for developing clinical nutrigenetics/nutrigenomics is the grow-
ing misconception that only very large studies can develop evidence for associations 
between single nucleotide polymorphisms (SNPs) and phenotypes. The use of genome-
wide profiling of common single nucleotide polymorphisms (SNPs) to identify such 
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associations has become common. These genome-wide association studies (GWAS) 
often screen thousands to millions of genes and their variants in thousands of subjects. 
In order to avoid the issue of multiplicity, and because of expected modest effect sizes, 
the scientific community has adopted strict definitions of statistical significance (e.g. 
p < 5 × 10–7 [1]), which dictate the need for large sample sizes typically involving thou-
sands of subjects. It is important to note that these definitions were adopted assuming 
an individual SNP has a small effect size and that large numbers of randomly selected 
SNPs are being screened for an association with a phenotype. Because of the enor-
mous number of genotype-phenotype associations tested in a genome-wide study, 
spurious associations will substantially outnumber true ones unless rigorous statisti-
cal thresholds are applied; smaller p values generally provide greater support for a true 
association. However, standard Bonferroni correction is overly conservative because 
it assumes the independence of all tests performed, but in many association studies 
markers are not independent because they are in linkage disequilibrium.
Sadly, this growing consensus for requiring p values < 5 × 10–7 makes clinical 
nutrigenetics/nutrigenomics virtually impossible. Inherently, such studies involve 
tens to hundreds but not thousands of subjects and often measure phenotype param-
eters that are not practically measured in large populations. If the phenotype to be 
explained is not easily detected in thousands of people, a population GWAS approach 
is not possible. For example, we later discuss studies on fatty liver that require con-
trolled diet conditions and mass resonance imaging. It might be possible to perform 
such studies on hundreds of people, but certainly not on tens of thousands. For clini-
cal nutrigenetics/nutrigenomics approaches to be viable we need to use study designs 
that allow less stringent p values than are used for GWAS studies. The appropriate 
design elements have already been considered by the scientific panel that suggested 
the rigorous p values for GWAS studies [1].
Reasons that are appropriate for lowering the threshold for calling a finding of a par-
ticular SNP-phenotype association are the selection of targeted SNPs based on knowl-
edge of the underlying processes causing the phenotype (e.g. selecting the gene for 
endogenous biosynthesis of a nutrient when studying the phenotype associated with 
deficiency of the nutrient), or selecting SNPs that are likely to result in defective pro-
tein products (such as non-synonymous coding SNPs) [1]. Selection of SNPs for which 
there is credible laboratory evidence or a validated in silico prediction a priori permits 
accepting a less rigorous p value; however, creating a credible biological hypothesis post 
hoc is not acceptable [1]. The lowering of the threshold for positively identifying a par-
ticular SNP-phenotype association must be declared before initiation of the analysis and 
not once the analysis has begun [1]. Additional information gathered from laboratory 
techniques, bioinformatic tools and a priori biological insight should be used to provide 
plausibility for interpreting genetic association findings [1]. It is important to limit the 
number of candidate SNPs considered as the number of multiple comparisons made in 
the analysis drives the possibility of false discovery. Inherently, small sample sizes can 
provide imprecise or incorrect estimates of the magnitude of the observed effects; thus, 
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the effect size must be large enough to stand out from such noise. An estimated effect 
size that is large (that is, with an odds ratio greater than 2) in a small but well-powered 
study can lend credence to an association, because unknown confounding factors are 
less likely to produce large effects [1]. Finally, replication of the association between 
SNP and phenotype in an independent study is important.
Thus, though some geneticists initially expressed doubts about results generated 
in clinical nutrigenetics/nutrigenomics because they reflexively expect large popula-
tion studies with very small p values, there are reasonable study designs under which 
clinical nutrigenetics/nutrigenomics is not only possible but practical (targeted and 
small number of SNPs studied based on biological insights with SNPs that have a 
large effect size and results that can be replicated).
Other Considerations before Undertaking Clinical Nutrigenetics/Nutrigenomics
In GWAS or clinical nutrigenetics/nutrigenomic studies, a haplotype associated with 
the phenotype of interest can be identified. The identified polymorphism is rarely 
the actual phenotype-causing variant, but is more likely to be correlated, or in link-
age disequilibrium with the functional SNP. Because SNP arrays do not assay every 
polymorphism in a genomic region, it is not possible to identify all the surround-
ing genetic variants that are correlated with the identified marker. However, we can 
define the boundaries within the gene where sequencing or subsequent fine-mapping 
experiments are appropriate [2].
Prototype Experiment in Nutrigenetics/Nutrigenomics: Studies on Choline 
Deficiency
The case study of the effects of genetic variation on dietary requirements for cho-
line provides an excellent example of how clinical nutrigenetics/nutrigenomics can 
be used. In these studies, SNPs in the gene responsible for de novo biosynthesis of 
choline were associated with the risk for developing choline deficiency (phenotype). 
When young women were found to be resistant to developing choline deficiency, the 
role of estrogen in induction of choline biosynthesis was identified. In addition, the 
effects of choline on epigenetic regulation of gene expression were studied.
Choline Metabolism
Choline is involved in 3 major pathways: acetylcholine synthesis, methyl donation via 
betaine, and phosphatidylcholine synthesis [3]. Choline, via its irreversible oxidation 
to betaine [4], methylates homocysteine to form methionine. This is the precursor for 
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synthesis of S-adenosylmethionine, the universal methyl donor needed for methyla-
tion of DNA, RNA and proteins. It is important to realize that choline, methionine 
and folate metabolism are inter-related at the step that homocysteine is methylated to 
form methionine [5]. Perturbing metabolism of one of the methyl-donors results in 
compensatory changes in the other methyl-donors due to the intermingling of these 
metabolic pathways [6–8]. Rats treated with the anti-folate, methotrexate, had dimin-
ished pools of choline metabolites in liver [7, 9]. Rats ingesting a choline-deficient 
diet had diminished tissue concentrations of methionine and S-adenosylmethionine 
[10] and doubled plasma homocysteine concentrations [11]. Humans who were cho-
line deficient, even when fed adequate amounts of folic acid, had diminished capacity 
to methylate homocysteine [12].
Most of the foods we eat contain various amounts of choline, choline esters and 
betaine [13], and in 2004 the United States Department of Agriculture released a data-
base on choline content in common foods (www.nal.usda.gov/fnic/foodcomp/Data/
Choline/Choline.pdf). The foods with greatest abundance of choline are of animal 
origin, especially eggs and liver. Human breast milk also is a good source of free cho-
line and choline esters [14], and the manufacturers of infant formulas have recently 
modified the content of choline compounds to levels similar with the ones in human 
breast milk [14, 15]. The only source of choline other than diet is de novo biosynthe-
sis of phosphatidylcholine catalyzed by phosphatidylethanolamine-N-methyltrans-
ferase (PEMT) in liver. This enzyme uses S-adenosylmethionine as a methyl donor 
and forms a new choline moiety [16].
Studies in humans show that dietary choline is required (reviewed in [3] and dis-
cussed later). In 1998, the US Institute of Medicine (Food and Nutrition Board) estab-
lished for the first time adequate intake (AI) and tolerable upper intake limit values for 
choline, based on limited human studies [17] The AI is 550 mg/70 kg body weight, with 
upward adjustment in pregnant and lactating women; the upper intake limit ranges 
from 1,000 mg/day in children to 3,500 mg/day in adults [17]. For some age categories 
for which adequate data were missing, AI values have been set by extrapolating from 
adult values (for ages 1–18 years), and from infants (for ages 7–12 months) [17]. The 
2005 NHANES survey reported that most people do not achieve the recommended 
AI for choline [18]. In participants from the Framingham Offspring Study the mean 
intake for total choline (energy adjusted) was below the AI values, with a mean intake 
of 313 mg/day; moreover, there was an inverse association between choline intake and 
plasma total homocysteine concentration in subjects with low folate intakes [19].
Consequences of Dietary Choline Deficiency in Humans
Using a clinical methodology for phenotyping individuals with respect to their sus-
ceptibility to developing organ dysfunction when fed a low choline diet [12, 20–22], 
adult men and women (pre- and postmenopausal) aged 18–70 years were admitted 
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to the General Clinical Research Center, UNC Chapel Hill and fed a standard diet 
containing a known amount of choline (550 mg/70 kg/day; baseline). On day 11, sub-
jects were placed on a diet containing <50 mg choline/day for up to 42 days. Blood 
and urine were collected to measure various experimental parameters of dietary 
choline status, and markers of organ dysfunction and liver fat were assessed. If at 
some point during the depletion period functional markers indicated organ dysfunc-
tion associated with choline deficiency, subjects were switched to a diet containing 
choline until replete. Most men and postmenopausal women fed low choline diets 
under controlled conditions developed reversible fatty liver (measure by mass reso-
nance spectroscopy) as well as liver and muscle damage, while 56% of premenopausal 
women were resistant to developing choline deficiency [22]. This observation imme-
diately suggested that estrogen moderated the dietary requirement for choline, and, 
indeed, estrogen induces the gene (PEMT) that makes endogenous synthesis of cho-
line possible [23]. The classic actions of estrogen occur through its receptors ERα 
and ERβ which bind as homodimers or heterodimers to estrogen response elements 
(EREs) in the promoters of many estrogen-responsive genes [24]. The consensus ERE 
(PuGGTCAnnnTGACCPy) [24] and some imperfect ERE half site motifs (ERE1/2) 
bind with ERα and ERβ [25–27]. There are multiple EREs in the promoter region(s) 
of the PEMT gene [23] and estrogen caused a marked up-regulation in PEMT mRNA 
expression and enzyme activity in human hepatocytes [23]. Thus, premenopausal 
women have an enhanced capacity for de novo biosynthesis of choline moiety. During 
pregnancy, estradiol concentration rises from approximately 1 to 60 nM at term [28, 
29], suggesting that capacity for endogenous synthesis of choline is highest during the 
period when females need to support fetal development.
Pregnancy and lactation are times when demand for choline is especially high. 
Large amounts of choline are delivered to the fetus across the placenta, where cho-
line transport systems pump it against a concentration gradient [30, 31] and deplete 
maternal plasma choline in humans [32]. Plasma or serum choline concentrations 
are 6- to 7-fold higher in the fetus and newborn than they are in the adult [33, 
34]. High levels of choline circulating in the neonate presumably ensure enhanced 
availability of choline to tissues. It is interesting that despite enhanced capacity to 
synthesize choline, the demand for this nutrient is so high that stores are depleted 
during pregnancy. Pregnant rats had diminished total liver choline compounds 
compared to non-mated controls and become as sensitive to choline-deficient diets 
as were male rats [35]. Because milk contains a great deal of choline, lactation fur-
ther increases maternal demand for choline, resulting in further depletion of tissue 
stores [35, 36]. These observations suggest that women depend on high rates of 
PEMT activity, as well as on dietary intake of choline to sustain normal pregnancy. 
Pemt–/– mice abort pregnancies at around 9–10 days of gestation unless fed supple-
mental choline (personal observation; [37]). As discussed later, choline nutriture 
during pregnancy is especially important because it influences brain development 
in the fetus [38–50].
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Genetic Variation in Dietary Requirements for Choline
Though premenopausal women should be resistant to choline deficiency because 
of estrogen, a significant portion of them (44%) developed organ dysfunction when 
deprived of choline [22]. Genetic variation likely underlies these differences in 
dietary requirements. As noted earlier, PEMT encodes for a protein responsible for 
endogenous formation of choline, and 78% of female carriers of the variant (C) allele 
in a SNP in the promoter region of the PEMT gene (rs12325817) developed organ 
dysfunction when fed a low choline diet (OR 25, p < 0.00005; p value based on 64 
women studied) [51]. The frequency of this variant allele was 0.74 in North Carolina. 
The risk haplotype abrogated the induction of PEMT by estrogen, while the wild-type 
haplotype did not [Resseguie et al., manuscript submitted]. The SNP rs12325817 is 
not located in an estrogen response element but probably is in linkage disequilibrium 
with a functional SNP within such a response element.
Other SNPs in choline metabolism genes may have some influence on the dietary 
requirements for choline, though the p values for these associations are not as robust 
as for rs12325817. The first of 2 SNPs in the coding region of the choline dehydro-
genase gene (CHDH; rs9001) had a protective effect on susceptibility to choline 
deficiency, while a second CHDH variant (rs12676) was associated with increased 
susceptibility [51]. We did not have the power in this study to identify any association 
of a SNP in the betaine:homocysteine methyltransferase gene (BHMT; rs3733890) 
with susceptibility to choline deficiency [51].
Genetic variants of genes in folate metabolism also modified the susceptibility 
of these subjects to choline deficiency [52]. Premenopausal women who were car-
riers of the very common 5,10-methylenetetrahydrofolate dehydrogenase-G1958A 
(MTHFD1; rs2236225) gene allele were more than 15 times as likely as non-carriers 
to develop signs of choline deficiency (p < 0.0001) on the low choline diet. Sixty-three 
percent of our study population had at least 1 allele for this SNP. The rs2236225 poly-
morphism alters the delicately balanced flux between 5,10-methylene tetrahydrofo-
late and 10-formyl tetrahydrofolate and thereby influences the availability of 5-methyl 
THF for homocysteine remethylation [53]. This increases demand for choline as a 
methyl-group donor. It is of interest that the risk of having a child with a neural tube 
defect increases in mothers with the rs2236225 SNP [54]. We did not have sufficient 
power in the study to detect any effects of other folate metabolism SNPs (C677T and 
A1298C polymorphisms of the 5,10-methylene tetrahydrofolate reductase gene and 
the A80C polymorphism of the reduced folate carrier 1 gene) [52].
Choline and Neural Development
Rats and mice fed a low choline diet in late pregnancy (gestational days 12 to 17 in 
mice, days 12 to 18 or 20 in rats) had reduced neural progenitor cell proliferation and 
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increased apoptosis in fetal hippocampus and cortex [38, 44, 55]. Similar outcomes 
were reported when pregnant mice are fed a low-folate diet [56], suggesting, again, 
potential synergistic mechanisms of action between folate and choline.
The mechanisms associating choline deficiency with decreased cell proliferation 
are, in part, related to the over-expression of cyclin-dependent kinase inhibitors 
(Cdkn) like p27Kip1 [40], p15Ink4b [40, 45] and Cdkn3 [45, 57], suggesting that 
choline deficiency inhibits cell proliferation by inducing G1 arrest due to the inhibi-
tion of the interaction between cyclin-dependent kinases and cyclins. Using mouse 
hippocampal and cortical progenitor cells exposed to choline deficiency for 48 h, 
oligonucleotide-array analysis of gene expression showed expression changes in more 
than a thousand genes, of which 331 were related to cell division, apoptosis, neuronal 
and glial differentiation, methyl metabolism, and calcium-binding protein ontology 
classes [58], consistent with the phenotype of reduced cell proliferation, increased 
apoptosis, and increased differentiation.
Choline Deficiency Alters Gene Expression via Epigenetic Mechanisms
Neural development is influenced by DNA methylation. Overall levels of methylation 
decrease as neuronal differentiation proceeds [59] and the treatment of neural pro-
genitor cells with demethylating agents induces them to differentiate into cholinergic 
and adrenergic neurons [60]. Although the relationship between nutrition and epige-
netics has been firmly established in the last few years [61], less is known about the role 
nutrition has in the epigenetic regulation of fetal brain development. Because dietary 
choline is an important player in the maintenance of the S-adenosylmethionine pool 
(the methyl donor for DNA methylation), along with folate and methionine, it is rea-
sonable to expect that choline influences the epigenetic status of the developing brain. 
Global DNA methylation is decreased in the neuroepithelial layer of the hippocam-
pus in choline deficient mouse fetal brains. Along with decreased global methyla-
tion, changes in gene-specific methylation were reported, where a cyclin-dependent 
kinase (Cdkn3) was hypo-methylated in its promoter by choline deficiency [45, 57] 
in the progenitor layer of the hippocampus. These alterations were associated with 
increased protein expression of this cyclin-dependent kinase inhibitor [45], and this 
model is consistent with previous findings showing that there is epigenetic regulation 
of cyclin-dependent kinase inhibitors that regulate cell proliferation [62].
Long-Lasting Consequences of Prenatal Choline Availability
The changes induced by dietary choline in fetal brain have long-lasting effects that alter 
brain function throughout life. Maternal dietary choline availability during late preg-
nancy was associated with long-lasting changes in the hippocampal function of the adult 
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Implications for Human Brain Development
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